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After 3 Decades, at Long Last,
a New Device to Deal With
Calciﬁc Lesions*Antonio Colombo, MD,yz
Vasileios F. Panoulas, MD, PHDyzx
Milan, Italy; and London, United Kingdom
In 1981, David Auth, a former University of Washington
professor of electrical engineering, invented rotational
atherectomy (RA): the “rotablator,” one of the longest-lived
devices in the ﬁeld of interventional cardiology. RA remains
a useful niche device for the percutaneous treatment of
complex lesions, usually as an adjunct to subsequent balloon
angioplasty and intracoronary stent placement. Fourrier et al.
(1) performed the ﬁrst case of RA in human coronary ar-
teries in 1988. Since then, RA has been a useful tool to
treat heavily calciﬁed, ﬁbrotic lesions and those undilatableSee page 510with balloon technology (2,3). Attempts to treat such
lesions solely with balloon angioplasty and intracoronary
stent placement often lead to incomplete stent deployment
with adverse future outcomes (4). Rotablation use with
subsequent drug-eluting stent (DES) implantation has been
proven safe with acceptable 9-month target lesion revascu-
larization (TLR) rates (w10%) (5). In a nonrandomized
comparison of heavily calciﬁed lesions in which DES were
delivered with or without the need of RA, similar TLR,
Q-wave myocardial infarction, and mortality rates were
observed between the 2 groups at 6 months (6). A ran-
domized comparison of DES versus RA with subsequent
DES in calciﬁc lesions appears difﬁcult to be executed
as only moderate calciﬁc lesions amenable to both treat-
ment strategies would be included. Randomized studies
on RA debulking and subsequent stenting versus isolated
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stock in Direct Flow, Santa Clara, California.sults (7-9). The ROSTER (Randomized Trial of Rotational
Atherectomy Versus Balloon Angioplasty for Diffuse In-
Stent Restenosis) trial (8) reported lower TLR rates among
the RA group at 9 months, whereas the ARTIST trial
(Angioplasty Versus Rotational Atherectomy for Treatment
of Diffuse In-Stent Restenosis Trial) (9) demonstrated
clinical superiority of a stenting-alone strategy. However,
the poor performance of the RA in the ARTIST trial was
attributed to underexpansion of the stents implanted
because of the low inﬂation pressures suggested by the study
protocol.
Three decades down the line, orbital atherectomy has
emerged as a new tool speciﬁcally conceived to deal with
calciﬁc coronary stenoses. In the pilot ORBIT I (Safety and
Feasibility of Orbital Atherectomy for the Treatment of
Calciﬁed Coronary Lesions) trial (10), the safety and perfor-
mance of the orbital atherectomy system for de novo calciﬁed
lesions was tested in 50 patients, with promising results. The
sequel study presented in this issue of JACC: Cardiovascular
Interventions, the ORBIT II (Pivotal Trial to Evaluate the
Safety and Efﬁcacy of the Orbital Atherectomy System in
Treating DeNovo, Severely Calciﬁed Coronary Lesions) trial
(11) lays out the larger experience of orbital atherectomy in
443 subjects recruited in 49 U.S. sites. We are very attracted
by the appearance of a new technology aimed to address
calciﬁed lesions. The vast majority of research efforts aiming
to tackle calciﬁc and ﬁbrotic lesions focus on developing
novel, low-proﬁle stent platforms that could be delivered even
in the hardest of lesions. However, the approach of stent
implantation without appropriate lesion preparation may lead
to suboptimal results even after high-pressure post-dilation.
This strategy is not necessarily due to a “naive stent delivery
attitude”; it represents the “interventionist’s survival instinct”
when dealing with difﬁcult lesions. Delivering the stent at
the lesion site is frequently considered a successful endpoint
regardless of residual lumen diameter stenosis or presence of
underexpansion.
The immediate question coming to mind is: “What is
wrong with RA?” The answer to this question should stem
from a randomized trial comparing head-to-head orbital
atherectomy to RA. We entirely agree with the investigators
that such a comparison is essential to demonstrate the
incremental beneﬁts of orbital over RA. Orbital has the
following main differences from RA:
1. As a result of the burr being constructed from 3 heli-
cally wound wires (like a spring), the size of the cutting
device can slightly vary according to the degree of
compression.
2. The crown, which comes at a ﬁxed 1.25-mm size, is
eccentric in shape, and therefore, orbits rather than
spins concentrically on the wire.
3. The orbital path of the device around the periphery of
the lumen allows the burr to attack the plaque, in
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520contrast with the burr of a rotational device, which
remains in one place. In orbital atherectomy, a healthy,
compliant tissue should ﬂex away, whereas ﬁbrotic
calciﬁc lesions would generate an opposing force,
allowing differential sanding.
4. The operator can control the speed of rotation with the
knowledge that a higher speed will create a deeper
rotational cut by increasing lateral pressure.
5. Differential and incomplete contact of the ablating
wires to the wall of the artery allows some blood ﬂow,
which ﬂushes debris and facilitates cooling, mini-
mizing the potential for ischemia and thermal trauma.
Both rotational and orbital atherectomy share the same
limitation: the need for a speciﬁc dedicated guidewire.
The ORBIT II study evaluated the feasibility and per-
formance of this new atherectomy device in calciﬁc lesions
in patients from a U.S. multicenter registry. First of all, it
is important to bear in mind the difﬁculties relating to the
accurate deﬁnition of “severely calciﬁc lesions.” The in-
vestigators report some speciﬁc features in an attempt to
standardize the inclusion criteria; nevertheless, readers
should be aware of unresolved limitations. The deﬁned
“performance goals” based on historic controls extracted
from RA literature are interesting, but have serious limita-
tions, despite sophisticated statistical analysis. We should
wait for a direct comparison between rotational and orbital
atherectomy before making any deﬁnite conclusions.
In line with the dictum “safety ﬁrst,” the primary safety
endpoint of this study, deﬁned as freedom from major
adverse cardiac events at 30 days for >83% of patients, was
met (major adverse cardiac event–free 30-day survival
w90%). However, we are surprised by the primary efﬁcacy
endpoint thresholds (residual stenosis under 50%, ﬁrst re-
ported in a paper by MacIsaac et al. [2] in 1995) selected
by the investigators, particularly when taking into account
that the reported mean residual post-stent diameter stenosis
was 5.8%. Future studies should use more contemporary
post-stenting residual stenosis cutoffs.
The main ﬁndings of the large multicenter experience are:
 The device was able to cross the majority of the lesions
in which the device was activated; only 2 lesions could
not be crossed.
 Stents were successfully delivered in almost all of the
lesions (98.2%) with good angiographic ﬁnal results.
The angiographic endpoint of residual lumen diameter
stenosis appears not fully informative compared with
the measurement of ﬁnal lumen cross-sectional area
using intravascular ultrasound.
 Complications such as periprocedural myocardial
infarction occurred at rates expected for “generic le-
sions” and were lower compared with other reports
utilizing RA in calciﬁc lesions (2,12). Unique is the
absence of slow-ﬂow or no-reﬂow.If the results presented in this registry are conﬁrmed in
real-life practice, we believe that percutaneous coronary in-
terventions will gain an important momentum, thanks to
a safe and effective tool designed to optimally prepare
calciﬁc and ﬁbrotic lesions. Without question, these new
devices (probably more to come) dedicated to dealing with
tough lesions will become important companions of bio-
resorbable scaffolds, whose performance relies on adequate
lesion preparation.
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